Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D

Shionogi’s April-December group operating profit tanked over 40% year on year, the company said on January 31. This is attributable to an increase in SGA expenses for its injectable antibiotic cefiderocol and COVID-19 R&D investments, coupled with a pullback from...read more